Literature DB >> 15071052

Modified colorimetric assay for susceptibility testing of azole antifungal drugs against Candida species.

Jian Chen1, Zhe Wan, Ruoyu Li.   

Abstract

We modified a rapid susceptibility assay (RSA) for antifungal susceptibility testing of azoles based upon glucose utilization. This modified RSA method provides quantitative endpoint readings in 6 h. In this study, the modified RSA and the National Committee for Clinical Laboratory Standards M27-A methods were used to determine the MICs of fluconazole and itraconazole for 118 Candida isolates. Yeast nitrogen base containing 0.12 g of glucose per liter was used for the modified RSA method. For fluconazole, agreement among assays within one or two twofold dilutions was 72.9 and 88.1%, respectively; for itraconazole, agreement within one or two twofold dilutions was 82.2 and 89.8%, respectively. These data suggest that the modified RSA method is a reliable and rapid method for azole antifungal susceptibility testing against Candida species.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15071052      PMCID: PMC387539          DOI: 10.1128/JCM.42.4.1790-1793.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Determination of antifungal MICs by a rapid susceptibility assay.

Authors:  M H Riesselman; K C Hazen; J E Cutler
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

2.  Comparison of a new colorimetric assay with the NCCLS broth microdilution method (M-27A) for antifungal drug MIC determination.

Authors:  R K Li; C M Elie; G E Clayton; M A Ciblak
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

3.  Predictors of adverse outcome in cancer patients with candidemia.

Authors:  E J Anaissie; J H Rex; O Uzun; S Vartivarian
Journal:  Am J Med       Date:  1998-03       Impact factor: 4.965

Review 4.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

5.  Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia.

Authors:  O Uzun; S Ascioglu; E J Anaissie; J H Rex
Journal:  Clin Infect Dis       Date:  2001-05-07       Impact factor: 9.079

6.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

7.  Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital.

Authors:  R Luzzati; G Amalfitano; L Lazzarini; F Soldani; S Bellino; M Solbiati; M C Danzi; S Vento; G Todeschini; C Vivenza; E Concia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-08       Impact factor: 3.267

8.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

9.  Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts.

Authors:  R A Fromtling; J N Galgiani; M A Pfaller; A Espinel-Ingroff; K F Bartizal; M S Bartlett; B A Body; C Frey; G Hall; G D Roberts
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

  9 in total
  1 in total

1.  Antifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy.

Authors:  Muireann Coen; Jennifer Bodkin; Damla Power; William A Bubb; Uwe Himmelreich; Philip W Kuchel; Tania C Sorrell
Journal:  Antimicrob Agents Chemother       Date:  2006-09-18       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.